Clinical Trial Update: Study of Alpelisib (BYL719) in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy in Patients With HER2-positive Advanced Breast Cancer With a PIK3CA Mutation [Phase 3]

View source ↗

Summary

Phase 3 clinical trial evaluating alpelisib in combination with trastuzumab and pertuzumab as maintenance therapy for HER2-positive advanced breast cancer with …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Alpelisib (alpelisib)
• Pertuzumab (pertuzumab)
• Trastuzumab (trastuzumab)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Advanced HER2+Breast Cancer | Phase 3 | Status: ACTIVE_NOT_RECRUITING